Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surgical excision versus MAL-PDT and 5-fluorouracil for Bowen's disease
NL-OMON49810Phase 4Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- May 2019
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methyl aminolevulinate and fluorouracil in Bowen disease (BD) and squamous cell carcinoma (SCC) (3 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Sustained clearance at 12 months post-treatment. Started May 2019; status: completed.
02
Drugs
methyl aminolevulinatefluorouracil
03
Conditions
Bowen disease (BD)squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NL-OMON49810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49810.